Effective Use of ALK Inhibitors in EML4::ALK Positive Lymphatic Malformations

Genetically-targeted medications are emerging as important therapies for lymphatic malformations (LMs) unresponsive to sirolimus. We describe two patients with EML4::ALK positive LMs, one with Gorham Stout Disease and one with a large genitourinary (GU) LM, who were successfully treated with ALK inhibitors. This report adds ALK inhibitors to the growing toolbox of molecularly-targeted therapies for LMs.